S&P 500   3,144.19 (+0.86%)
DOW   27,959.63 (+1.02%)
QQQ   204.50 (+1.02%)
AAPL   269.13 (+1.34%)
FB   200.41 (+0.53%)
GOOGL   1,339.58 (+1.56%)
AMZN   1,753.54 (-0.41%)
CGC   18.61 (+0.05%)
NVDA   212.11 (+1.28%)
TSLA   336.42 (+1.02%)
T   38.37 (+0.47%)
AMD   39.86 (+0.40%)
PRI   136.10 (+1.34%)
NFLX   304.60 (+0.09%)
BAC   33.74 (+1.96%)
GILD   66.91 (+0.24%)
S&P 500   3,144.19 (+0.86%)
DOW   27,959.63 (+1.02%)
QQQ   204.50 (+1.02%)
AAPL   269.13 (+1.34%)
FB   200.41 (+0.53%)
GOOGL   1,339.58 (+1.56%)
AMZN   1,753.54 (-0.41%)
CGC   18.61 (+0.05%)
NVDA   212.11 (+1.28%)
TSLA   336.42 (+1.02%)
T   38.37 (+0.47%)
AMD   39.86 (+0.40%)
PRI   136.10 (+1.34%)
NFLX   304.60 (+0.09%)
BAC   33.74 (+1.96%)
GILD   66.91 (+0.24%)
S&P 500   3,144.19 (+0.86%)
DOW   27,959.63 (+1.02%)
QQQ   204.50 (+1.02%)
AAPL   269.13 (+1.34%)
FB   200.41 (+0.53%)
GOOGL   1,339.58 (+1.56%)
AMZN   1,753.54 (-0.41%)
CGC   18.61 (+0.05%)
NVDA   212.11 (+1.28%)
TSLA   336.42 (+1.02%)
T   38.37 (+0.47%)
AMD   39.86 (+0.40%)
PRI   136.10 (+1.34%)
NFLX   304.60 (+0.09%)
BAC   33.74 (+1.96%)
GILD   66.91 (+0.24%)
S&P 500   3,144.19 (+0.86%)
DOW   27,959.63 (+1.02%)
QQQ   204.50 (+1.02%)
AAPL   269.13 (+1.34%)
FB   200.41 (+0.53%)
GOOGL   1,339.58 (+1.56%)
AMZN   1,753.54 (-0.41%)
CGC   18.61 (+0.05%)
NVDA   212.11 (+1.28%)
TSLA   336.42 (+1.02%)
T   38.37 (+0.47%)
AMD   39.86 (+0.40%)
PRI   136.10 (+1.34%)
NFLX   304.60 (+0.09%)
BAC   33.74 (+1.96%)
GILD   66.91 (+0.24%)
Log in

OTCMKTS:PXSLY - Pharmaxis Stock Price, Forecast & News

$2.48
0.00 (0.00 %)
(As of 12/6/2019 10:17 AM ET)
Today's Range
$2.48
Now: $2.48
$2.48
50-Day Range
$2.09
MA: $2.21
$2.59
52-Week Range
$1.75
Now: $2.48
$3.12
VolumeN/A
Average Volume76 shs
Market Capitalization$65.20 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.63
Pharmaxis Ltd engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, liver, IPF, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PXSLY
CUSIPN/A
Phone61-2-9454-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.41 million
Cash Flow$0.23 per share
Book Value$0.40 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$65.20 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PXSLY News and Ratings via Email

Sign-up to receive the latest news and ratings for PXSLY and its competitors with MarketBeat's FREE daily newsletter.


Pharmaxis (OTCMKTS:PXSLY) Frequently Asked Questions

What is Pharmaxis' stock symbol?

Pharmaxis trades on the OTCMKTS under the ticker symbol "PXSLY."

Has Pharmaxis been receiving favorable news coverage?

Press coverage about PXSLY stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pharmaxis earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Pharmaxis.

Who are some of Pharmaxis' key competitors?

Who are Pharmaxis' key executives?

Pharmaxis' management team includes the folowing people:
  • Mr. Gary Jonathan Phillips, CEO & Director (Age 57)
  • Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 62)
  • Mr. Wolfgang G. Jarolimek B.Sc. Ph.D., Head of Drug Discovery (Age 54)
  • Dr. Brett Charlton MBBS Ph.D., Medical Director (Age 62)
  • Ms. Kristen Morgan BSc, PGDipBusAdmin, MMedSc, Officer of Alliance Management & Medical and Regulatory Affairs (Age 46)

How do I buy shares of Pharmaxis?

Shares of PXSLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Pharmaxis' stock price today?

One share of PXSLY stock can currently be purchased for approximately $2.48.

How big of a company is Pharmaxis?

Pharmaxis has a market capitalization of $65.20 million and generates $39.41 million in revenue each year. View Additional Information About Pharmaxis.

What is Pharmaxis' official website?

The official website for Pharmaxis is http://www.pharmaxis.com.au/.

How can I contact Pharmaxis?

Pharmaxis' mailing address is 20 RODBOROUGH ROAD, FRENCHS FOREST C3, 2086. The company can be reached via phone at 61-2-9454-7200 or via email at [email protected]


MarketBeat Community Rating for Pharmaxis (OTCMKTS PXSLY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  104
MarketBeat's community ratings are surveys of what our community members think about Pharmaxis and other stocks. Vote "Outperform" if you believe PXSLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PXSLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel